Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NASH - Nonalcoholic Steatohepatitis Clear all
Completed Phase 2 Interventional Results available

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NCT05415722
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-501, TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
35
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 1, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 1, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672866
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH

NCT04872777
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Noom Healthy Weight
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Marietta, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

NCT04874233
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HU6, Placebo
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
28 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Vitamin E Dosing Study

NCT04801849
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Vitamin E, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Not applicable Interventional Results available

LAGB as a Treatment for Morbid Obesity in Adolescents

NCT01045499
View directory record Official record
Conditions
Morbid Obesity, Obstructive Sleep Apnea Syndrome, Metabolic Syndrome, Insulin Resistance, Nonalcoholic Fatty Liver Disease
Interventions
Laparoscopic adjustable gastric banding (Allergan Lap Band)
Device
Lead sponsor
Jeffrey L Zitsman, MD
Other
Eligibility
13 Years to 19 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 1, 2026, 9:57 AM EDT
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Conditionally Increased Output (CIO) Enhanced Ultrasound System

NCT05792423
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
Interventions
GE ultrasound system with increased acoustic output settings
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 3 Interventional

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes

NCT02132442
View directory record Official record
Conditions
Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
Interventions
Ergocalciferol, placebo
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Comparison of Dietary Sugar Reduction Methods

NCT04186793
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Guided Grocery Shopping (GGS), Diet Provision Group
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 16 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Chandler, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

NCT05022693
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NCT03748628
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 1, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03053063
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
128
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Cenicriviroc (CVC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

NCT02856555
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Firsocostat, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Coronado, California • Foster City, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 1, 2026, 9:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance

NCT05165706
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes, Insulin Resistance, Obesity, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver, Diet Modification
Interventions
Dietary Intervention Mediterranean Low Carbohydrate Diet, Dietary Intervention Standard Low Carbohydrate Diet, Dietary Intervention Standard Low Fat Diet
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

NCT04321031
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions
Placebo, PF-06865571, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
184
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 1, 2026, 9:57 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

NCT02933554
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions
Embospheres Microspheres
Device
Lead sponsor
Keith Pereira, MD:
Other
Eligibility
22 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Not applicable Interventional

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

NCT05370053
View directory record Official record
Conditions
Fatty Liver, NAFLD
Interventions
ELF Test
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 1, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

NCT01244503
View directory record Official record
Conditions
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
Interventions
Sodium Octanoate Breath Test
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Sep 1, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NCT05327127
View directory record Official record
Conditions
NASH
Interventions
K-877-ER, CSG452, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lincoln, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 1, 2026, 9:57 AM EDT
Withdrawn Early Phase 1 Interventional

ER Stress in NAFLD

NCT01807910
View directory record Official record
Conditions
Obesity, NAFLD
Interventions
methyl-D9-choline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 1, 2026, 9:57 AM EDT